These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 36116233)

  • 1. Boosting caffeic acid performance as antioxidant and monoamine oxidase B/catechol-O-methyltransferase inhibitor.
    Chavarria D; Benfeito S; Soares P; Lima C; Garrido J; Serrão P; Soares-da-Silva P; Remião F; Oliveira PJ; Borges F
    Eur J Med Chem; 2022 Dec; 243():114740. PubMed ID: 36116233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nitrocatechol Derivatives of Chalcone as Inhibitors of Monoamine Oxidase and Catechol-O-Methyltransferase.
    Engelbrecht I; Petzer JP; Petzer A
    Cent Nerv Syst Agents Med Chem; 2018; 18(2):115-127. PubMed ID: 29697034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The inhibition of catechol O-methyltransferase and monoamine oxidase by tetralone and indanone derivatives substituted with the nitrocatechol moiety.
    de Beer AD; Legoabe LJ; Petzer A; Petzer JP
    Bioorg Chem; 2021 Sep; 114():105130. PubMed ID: 34225162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of nitrocatechol chalcone and pyrazoline derivatives as inhibitors of catechol-O-methyltransferase and monoamine oxidase.
    Hitge R; Smit S; Petzer A; Petzer JP
    Bioorg Med Chem Lett; 2020 Jun; 30(12):127188. PubMed ID: 32299731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of Selected Natural Compounds as Dual Inhibitors of Catechol-O-Methyltransferase and Monoamine Oxidase.
    Engelbrecht I; Petzer JP; Petzer A
    Cent Nerv Syst Agents Med Chem; 2019; 19(2):133-145. PubMed ID: 31258092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Catechol-O-methyltransferase and monoamine oxidase B inhibitory activities of Australian bee pollen.
    Watanabe C; Yanagihara A; Miyata R; Mitsui T; Honda C; Fujinami D; Kumazawa S
    Biosci Biotechnol Biochem; 2024 May; 88(6):665-670. PubMed ID: 38561637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification and optimization of nitrophenolic analogues as dopamine metabolic enzyme inhibitors for the treatment of Parkinson's disease.
    Zou M; Wu Y; Lan Y; Xie H; Sun H; Liu W; Feng F; Jiang X
    Bioorg Chem; 2024 Jul; 148():107488. PubMed ID: 38797066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term Effectiveness of Adjuvant Treatment With Catechol-O-Methyltransferase or Monoamine Oxidase B Inhibitors Compared With Dopamine Agonists Among Patients With Parkinson Disease Uncontrolled by Levodopa Therapy: The PD MED Randomized Clinical Trial.
    Gray R; Patel S; Ives N; Rick C; Woolley R; Muzerengi S; Gray A; Jenkinson C; McIntosh E; Wheatley K; Williams A; Clarke CE;
    JAMA Neurol; 2022 Feb; 79(2):131-140. PubMed ID: 34962574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The role of inhibitors of COMT and MAO-B in the therapy of Parkinson's disease].
    Woitalla D; Krüger R; Lorenzl S; Müller T; Oelwein G; Storch A; Wolz M; Wüllner U
    Fortschr Neurol Psychiatr; 2020 Sep; 88(9):620-633. PubMed ID: 32588409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibitory potential of plant secondary metabolites on anti-Parkinsonian drug targets: Relevance to pathophysiology, and motor and non-motor behavioural abnormalities.
    Mazumder MK; Borah A; Choudhury S
    Med Hypotheses; 2020 Apr; 137():109544. PubMed ID: 31954292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of novel and potent safinamide-based derivatives as highly selective hMAO-B inhibitors for treatment of Parkinson's disease (PD): Design, synthesis, in vitro, in vivo and in silico biological studies.
    Elkamhawy A; Paik S; Park JH; Kim HJ; Hassan AHE; Lee K; Park KD; Roh EJ
    Bioorg Chem; 2021 Oct; 115():105233. PubMed ID: 34390968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Catechol-O-methyltransferase inhibitors in Parkinson's disease.
    Müller T
    Drugs; 2015 Feb; 75(2):157-74. PubMed ID: 25559423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of Blood-Brain Barrier Permeable Nitrocatechol-Based Catechol O-Methyltransferase Inhibitors with Reduced Potential for Hepatotoxicity.
    Silva T; Mohamed T; Shakeri A; Rao PP; Martínez-González L; Pérez DI; Martínez A; Valente MJ; Garrido J; Uriarte E; Serrão P; Soares-da-Silva P; Remião F; Borges F
    J Med Chem; 2016 Aug; 59(16):7584-97. PubMed ID: 27463695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of monoamine oxidase and catechol O-methyltransferase in dopaminergic neurotransmission.
    Napolitano A; Cesura AM; Da Prada M
    J Neural Transm Suppl; 1995; 45():35-45. PubMed ID: 8748607
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simultaneous inhibition of catechol-O-methyltransferase and monoamine oxidase A: effects on hemodynamics and catecholamine metabolism in healthy volunteers.
    Illi A; Sundberg S; Ojala-Karlsson P; Scheinin M; Gordin A
    Clin Pharmacol Ther; 1996 Apr; 59(4):450-7. PubMed ID: 8612391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nordihydroguaiaretic Acid as a Novel Substrate and Inhibitor of Catechol
    Kim JH; Lee J; Jeong H; Bang MS; Jeong JH; Chang M
    Molecules; 2021 Apr; 26(7):. PubMed ID: 33916785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacodynamic evaluation of novel Catechol-O-methyltransferase inhibitors.
    Pinheiro SD; Serrão MP; Silva T; Borges F; Soares-da-Silva P
    Eur J Pharmacol; 2019 Mar; 847():53-60. PubMed ID: 30685433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel, non-nitrocatechol catechol-O-methyltransferase inhibitors modulate dopamine neurotransmission in the frontal cortex and improve cognitive flexibility.
    Byers S; Buchler IP; DePasquale M; Rowley HL; Kulkarni RS; Pinder L; Kolobova A; Li C; Au V; Akuma D; Zhang G; Wei H; Cheetham SC; Barrow JC; Carr GV
    Psychopharmacology (Berl); 2020 Sep; 237(9):2695-2707. PubMed ID: 32474681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A semiempirical study on inhibition of catechol O-methyltransferase by substituted catechols.
    Ovaska M; Yliniemelä A
    J Comput Aided Mol Des; 1998 May; 12(3):301-7. PubMed ID: 9749372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of monoamine oxidase and catechol-O-methyltransferase inhibition on dopamine turnover: a PET study with 6-[18F]L-DOPA.
    Doudet DJ; Chan GL; Holden JE; Pate BD; Morrison KS; Calne DB; Ruth TJ
    Eur J Pharmacol; 1997 Sep; 334(1):31-8. PubMed ID: 9346324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.